326 related articles for article (PubMed ID: 25773986)
1. A test of lens opacity as an indicator of preclinical Alzheimer Disease.
Bei L; Shui YB; Bai F; Nelson SK; Van Stavern GP; Beebe DC
Exp Eye Res; 2015 Nov; 140():117-123. PubMed ID: 25773986
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.
Sutphen CL; Jasielec MS; Shah AR; Macy EM; Xiong C; Vlassenko AG; Benzinger TL; Stoops EE; Vanderstichele HM; Brix B; Darby HD; Vandijck ML; Ladenson JH; Morris JC; Holtzman DM; Fagan AM
JAMA Neurol; 2015 Sep; 72(9):1029-42. PubMed ID: 26147946
[TBL] [Abstract][Full Text] [Related]
3. Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer Disease Biomarker Levels.
Babulal GM; Ghoshal N; Head D; Vernon EK; Holtzman DM; Benzinger TLS; Fagan AM; Morris JC; Roe CM
Am J Geriatr Psychiatry; 2016 Nov; 24(11):1095-1104. PubMed ID: 27426238
[TBL] [Abstract][Full Text] [Related]
4. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
[TBL] [Abstract][Full Text] [Related]
5. Circadian Rest-Activity Pattern Changes in Aging and Preclinical Alzheimer Disease.
Musiek ES; Bhimasani M; Zangrilli MA; Morris JC; Holtzman DM; Ju YS
JAMA Neurol; 2018 May; 75(5):582-590. PubMed ID: 29379963
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer's Disease.
Lewczuk P; Matzen A; Blennow K; Parnetti L; Molinuevo JL; Eusebi P; Kornhuber J; Morris JC; Fagan AM
J Alzheimers Dis; 2017; 55(2):813-822. PubMed ID: 27792012
[TBL] [Abstract][Full Text] [Related]
7. Proximity to Parental Symptom Onset and Amyloid-β Burden in Sporadic Alzheimer Disease.
Villeneuve S; Vogel JW; Gonneaud J; Pichet Binette A; Rosa-Neto P; Gauthier S; Bateman RJ; Fagan AM; Morris JC; Benzinger TLS; Johnson SC; Breitner JCS; Poirier J;
JAMA Neurol; 2018 May; 75(5):608-619. PubMed ID: 29482212
[TBL] [Abstract][Full Text] [Related]
8. Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease.
Vlassenko AG; McCue L; Jasielec MS; Su Y; Gordon BA; Xiong C; Holtzman DM; Benzinger TL; Morris JC; Fagan AM
Ann Neurol; 2016 Sep; 80(3):379-87. PubMed ID: 27398953
[TBL] [Abstract][Full Text] [Related]
9. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
[TBL] [Abstract][Full Text] [Related]
10. Role of family history for Alzheimer biomarker abnormalities in the adult children study.
Xiong C; Roe CM; Buckles V; Fagan A; Holtzman D; Balota D; Duchek J; Storandt M; Mintun M; Grant E; Snyder AZ; Head D; Benzinger TL; Mettenburg J; Csernansky J; Morris JC
Arch Neurol; 2011 Oct; 68(10):1313-9. PubMed ID: 21987546
[TBL] [Abstract][Full Text] [Related]
11. Pittsburgh compound B-negative dementia: a possibility of misdiagnosis of patients with non-alzheimer disease-type dementia as having AD.
Shimada H; Ataka S; Takeuchi J; Mori H; Wada Y; Watanabe Y; Miki T
J Geriatr Psychiatry Neurol; 2011 Sep; 24(3):123-6. PubMed ID: 21750305
[TBL] [Abstract][Full Text] [Related]
12. Association of Preclinical Alzheimer Disease With Optical Coherence Tomographic Angiography Findings.
O'Bryhim BE; Apte RS; Kung N; Coble D; Van Stavern GP
JAMA Ophthalmol; 2018 Nov; 136(11):1242-1248. PubMed ID: 30352114
[TBL] [Abstract][Full Text] [Related]
13. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
14. Use of amyloid-PET to determine cutpoints for CSF markers: A multicenter study.
Zwan MD; Rinne JO; Hasselbalch SG; Nordberg A; Lleó A; Herukka SK; Soininen H; Law I; Bahl JM; Carter SF; Fortea J; Blesa R; Teunissen CE; Bouwman FH; van Berckel BN; Visser PJ
Neurology; 2016 Jan; 86(1):50-8. PubMed ID: 26468410
[TBL] [Abstract][Full Text] [Related]
15. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease.
Morris JC; Roe CM; Grant EA; Head D; Storandt M; Goate AM; Fagan AM; Holtzman DM; Mintun MA
Arch Neurol; 2009 Dec; 66(12):1469-75. PubMed ID: 20008650
[TBL] [Abstract][Full Text] [Related]
16. Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report.
Cairns NJ; Ikonomovic MD; Benzinger T; Storandt M; Fagan AM; Shah AR; Reinwald LT; Carter D; Felton A; Holtzman DM; Mintun MA; Klunk WE; Morris JC
Arch Neurol; 2009 Dec; 66(12):1557-62. PubMed ID: 20008664
[TBL] [Abstract][Full Text] [Related]
17. Incident cognitive impairment: longitudinal changes in molecular, structural and cognitive biomarkers.
Roe CM; Ances BM; Head D; Babulal GM; Stout SH; Grant EA; Hassenstab J; Xiong C; Holtzman DM; Benzinger TLS; Schindler SE; Fagan AM; Morris JC
Brain; 2018 Nov; 141(11):3233-3248. PubMed ID: 30304397
[TBL] [Abstract][Full Text] [Related]
18. A comparison of the diagnostic sensitivity of MRI, CBF-SPECT, FDG-PET and cerebrospinal fluid biomarkers for detecting Alzheimer's disease in a memory clinic.
Morinaga A; Ono K; Ikeda T; Ikeda Y; Shima K; Noguchi-Shinohara M; Samuraki M; Yanase D; Yoshita M; Iwasa K; Mastunari I; Yamada M
Dement Geriatr Cogn Disord; 2010; 30(4):285-92. PubMed ID: 20861634
[TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.
Tarawneh R; Head D; Allison S; Buckles V; Fagan AM; Ladenson JH; Morris JC; Holtzman DM
JAMA Neurol; 2015 Jun; 72(6):656-65. PubMed ID: 25867677
[TBL] [Abstract][Full Text] [Related]
20. Clinical features of Pittsburgh compound-B-negative dementia.
Takeuchi J; Shimada H; Ataka S; Kawabe J; Mori H; Mizuno K; Wada Y; Shiomi S; Watanabe Y; Miki T
Dement Geriatr Cogn Disord; 2012; 34(2):112-20. PubMed ID: 22947919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
